Department of Chemistry and Department of Bioscience and Biomedical Engineering, IIT Bhilai
The RMM Group designs metal complexes that act as smart MRI and optical probes to see inside tumours, as theranostic and therapeutic agents that detect and treat cancer, and as bioinspired catalysts that activate oxygen and carbon dioxide .
Associate Professor & Head of Deparment
Department of Chemistry, IIT Bhilai
Our group focuses on "interdisciplinary research" that involves the design and synthesis of carefully tailored molecules to act as smart MRI and optical probes to target tumours and understand their mechanism. Our research aims to use biologically inspired metal complexes as probes to understand complex biochemical processes in tumours. We are using these bioinspired imaging probes and our chemistry knowledge to image and quantify the reactive oxygen species (ROS), reactive nitrogen species (RNS), and other mobilities produced via the redox process within the tumor cells. We are working to place these molecules in clinical trials as novel therapeutic or diagnostic agents in the near future.
On the other hand, we are synthesizing a library of architecturally designed bioinspired coordination complexes with interesting structural, spectral, redox, and biological properties. Many of these complexes are demonstrated as synthetic analogues of metalloenzymes or as bioinspired catalysts for activating small molecules such as dioxygen and carbon dioxide. In all our projects, we try to accomplish our objectives through an appropriate combination of design, synthesis, and validation. As a result, the research projects in the group tend to be highly interdisciplinary in nature, involving bioinorganic chemistry, biochemistry, spectroscopy, and multistep organic synthesis. We named our group "Bioinorganic Chemistry and Chemical Biology," where chemists and biologists work together to address Health issues.
Chemists and biologists working together on health problems, combining design, synthesis and biological validation.
Fe(II) macrocycles as pH-responsive PARACEST agents, and Fe(III)-catecholate complexes as dual-modal T1 MRI and optical agents for nitric oxide and acidic tumour pH. Biotin conjugation raises the amount of agent delivered to tumours. Mn(II/III) complexes serve as redox-responsive agents sensitive to L-cysteine.
Fe(II), Ni(II) and Cu(II) complexes as models for cysteine dioxygenase, diketone dioxygenase and copper monooxygenases, and as catalysts for aromatic C-H bond hydroxylation, studied with spectroscopy and computation.
Bioinspired Cu(II) and Ni(II) complexes that fix atmospheric CO₂ under mild conditions and convert it into cyclic carbonates and carboxylic acids, with crystal structures of the CO₂-derived intermediates.
The Cancer Biology Research Group is dedicated to advancing precision oncology through the development of innovative nanomedicine-based approaches for targeted cancer therapy. The group’s research encompasses diverse biocompatible delivery platforms, including protein-based nanocages, engineered nanoparticles, liposomes, and hybrid nanostructures, with an emphasis on improving tumor-specific drug delivery, therapeutic bioavailability, and treatment selectivity while minimizing toxicity to healthy tissues.
A major research focus involves metal-dependent regulated cell death, particularly ferroptosis, and its therapeutic exploitation against cancer. Research is conducted using cervical, breast, and colorectal cancer models, encompassing investigations from cellular viability and cytotoxicity to molecular mechanisms, gene regulation, and protein expression associated with therapeutic responses.
The group also explores cancer theranostics through the development of multifunctional molecules and nanoplatforms that integrate diagnostic imaging with therapeutic applications, enabling image-guided cancer intervention. The group aims to bridge nanotechnology and cancer biology to advance innovative, targeted, and multifunctional therapeutic strategies.